.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Poster

eP167

A Phase 1 study of fianlimab in combination with cemiplimab in patients with anti–PD-1/L1-experienced cutaneous squamous cell carcinoma

Beitrag in

Selbststudium: Non Melanoma Skin Cancer: PEK und BCC

Mitwirkende

John Kaczmar (North Charleston, SC, US), Kyriakos P. Papadopoulos (San Antonio, TX, US), George Ansstas (St. Louis, MO, US), Ariel Birnbaum (Providence, RI, US), Janice Mehnert (New Brunswick, NJ, US), Omid Hamid (Los Angeles, CA, US), Brett G.M. Hughes (Brisbane, AU), Guilherme Rabinowits (Miami, FL, US), Alexander Z. Wei (New York, NY, US), Melinda Yushak (Atlanta, GA, US), Jayakumar Mani (Tarrytown, NY, US), Fang Fang (Tarrytown, NY, US), JuAn Wang (Tarrytown, NY, US), Glenn Kroog (Tarrytown, NY, US), Mark Salvati (Tarrytown, NY, US), Israel Lowy (Tarrytown, NY, US), Matthew G. Fury (Tarrytown, NY, US)